Fundraising FoxAimmune Therapeutics
Unicorn exit · $2.6BAcquired4 known investors
Find your way into Aimmune Therapeutics
Sign up to find every way you can get introduced to Aimmune Therapeutics
- Your email: who you already know at Aimmune Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Aimmune Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Acquired by Nestlé Health Science August 2020 · $2.6B (approximately $2.6 billion, $34.50 per share in cash) · source ↗
Aimmune Therapeutics developed desensitization treatments for life-threatening food allergies, including Palforzia, the first FDA-approved peanut allergy treatment.
Investors · 4
How we know: Aisling Capital's portfolio page · a partner's Signal profile · Not right? Tell us
How we know: Foresite Capital's portfolio page · Not right? Tell us
How we know: Longitude Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Founder mafia
2 people who came through Aimmune Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does Aimmune Therapeutics do?
- Aimmune Therapeutics developed desensitization treatments for life-threatening food allergies, including Palforzia, the first FDA-approved peanut allergy treatment.
- Who are Aimmune Therapeutics's investors?
- Aimmune Therapeutics's investors include Aisling Capital, Foresite Capital, Longitude Capital, Menlo Ventures.